ADRB1 and osteosarcoma: Indeed, the systemic treatment with the β1-AR antagonist atenolol did not affect osteosarcoma tumor growth, while the β1/2- and β3-ARs antagonists, propranolol and SR59230A respectively, reduced osteosarcoma tumor growth and were also able to modulate the mechanical allodynia developed with the tumor growth.